Turnstone Biologics Corp.
TSBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $19,306 | $73,300 | $101,293 |
| % Growth | -100% | -73.7% | -27.6% | – |
| Cost of Goods Sold | $1,835 | $2,800 | $2,200 | $2,012 |
| Gross Profit | -$1,835 | $16,506 | $71,100 | $99,281 |
| % Margin | – | 85.5% | 97% | 98% |
| R&D Expenses | $56,104 | $60,491 | $84,503 | $52,742 |
| G&A Expenses | $16,390 | $17,847 | $18,223 | $13,546 |
| SG&A Expenses | $16,390 | $17,847 | $18,223 | $13,546 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,011 | -$3,700 | $0 | $0 |
| Operating Expenses | $71,483 | $74,638 | $102,726 | $66,288 |
| Operating Income | -$72,494 | -$58,132 | -$31,626 | $32,993 |
| % Margin | – | -301.1% | -43.1% | 32.6% |
| Other Income/Exp. Net | $1,694 | $2,646 | $933 | $708 |
| Pre-Tax Income | -$70,800 | -$55,486 | -$30,693 | $33,701 |
| Tax Expense | $37 | -$286 | $141 | $432 |
| Net Income | -$70,837 | -$55,200 | -$30,834 | $33,269 |
| % Margin | – | -285.9% | -42.1% | 32.8% |
| EPS | -3.07 | -2.73 | -1.39 | 1.5 |
| % Growth | -12.5% | -96.4% | -192.7% | – |
| EPS Diluted | -3.07 | -2.73 | -1.39 | 1.5 |
| Weighted Avg Shares Out | 23,037 | 20,205 | 22,189 | 22,189 |
| Weighted Avg Shares Out Dil | 23,037 | 20,205 | 22,189 | 22,189 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,835 | $2,798 | $2,200 | $2,012 |
| EBITDA | -$68,965 | -$56,234 | -$28,493 | $35,713 |
| % Margin | – | -291.3% | -38.9% | 35.3% |